Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Get Free Report)'s share price was down 0.9% during trading on Thursday . The stock traded as low as $25.54 and last traded at $26.65. Approximately 26,391 shares were traded during mid-day trading, an increase of 18% from the average daily volume of 22,347 shares. The stock had previously closed at $26.88.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on TVRD. Oppenheimer assumed coverage on Tvardi Therapeutics in a report on Wednesday, May 21st. They set an "outperform" rating and a $65.00 price target on the stock. Cantor Fitzgerald assumed coverage on Tvardi Therapeutics in a research report on Friday, July 11th. They set an "overweight" rating and a $52.00 price objective for the company. Piper Sandler assumed coverage on Tvardi Therapeutics in a research note on Thursday, June 12th. They set an "overweight" rating and a $78.00 target price on the stock. Wall Street Zen upgraded Tvardi Therapeutics to a "hold" rating in a report on Saturday, May 24th. Finally, Raymond James Financial began coverage on shares of Tvardi Therapeutics in a report on Monday, July 14th. They set an "outperform" rating and a $62.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $64.25.
Read Our Latest Stock Report on Tvardi Therapeutics
Tvardi Therapeutics Stock Up 4.7%
The stock's 50-day simple moving average is $25.24.
Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.
Institutional Trading of Tvardi Therapeutics
Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC acquired a new stake in Tvardi Therapeutics during the second quarter valued at $2,617,000. Marshall Wace LLP acquired a new stake in Tvardi Therapeutics during the second quarter valued at $583,000. Bank of America Corp DE acquired a new stake in Tvardi Therapeutics during the second quarter valued at $399,000. New York State Common Retirement Fund acquired a new stake in shares of Tvardi Therapeutics in the second quarter worth about $92,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Tvardi Therapeutics in the second quarter worth about $80,000. Institutional investors and hedge funds own 44.66% of the company's stock.
Tvardi Therapeutics Company Profile
(
Get Free Report)
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Featured Stories
Before you consider Tvardi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tvardi Therapeutics wasn't on the list.
While Tvardi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
